<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01596803</url>
  </required_header>
  <id_info>
    <org_study_id>UF 8426</org_study_id>
    <nct_id>NCT01596803</nct_id>
  </id_info>
  <brief_title>Effects Antioxidants Supplementation on Muscular Function Patients Facioscapulohumeral Dystrophy (FSHD)</brief_title>
  <acronym>FSHD</acronym>
  <official_title>Effects of Antioxidants Supplementation on Muscular Function of Patients Affected by Facioscapulohumeral Dystrophy (FSHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clinical Research Project 2010</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Association Amis FSH France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>FSH Dutch Fondation The Netherland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      On the basis of published data and the investigators' results indicating that oxidative
      stress may contribute to the peripheral skeletal muscle dysfunction in patients with FSHD,
      the investigators propose a study to test whether or not an antioxidant supplementation has a
      therapeutic interest for patients with FSHD. Their results have important implications for
      the successful implementation of rational antioxidant therapy in FSHD in which cell loss
      could be linked to oxidative stress.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will compare the effect of the therapeutic interest of an antioxidant
      supplementation on the functional deficits and the molecular muscle abnormalities into two
      groups of patients affected by FSHD, one treated with the antioxidant supplementation during
      17 weeks. The antioxidant by capsule consisted of:Vitamin E (400 mg /day), Selenium (200
      µg/day in the form of selenomethionine), Vitamin C (500 mg/day), Zinc (25 mg/day in the form
      of gluconate). The second one treated with a placebo during 17 weeks. Patients will be
      assigned to intervention groups by chance, and neither physician, nor patient, will know
      which product is administrated (study in &quot;double blind&quot;).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of muscle effort tolerance after antioxidant supplementation</measure>
    <time_frame>duration study 3 years</time_frame>
    <description>17-weeks evaluation of an antioxidant supplementation in order to modulate or delay oxidative insult that could be useful to maintain FSHD muscle function. At T0, each patient will perform functionnal evaluation (Exercise Tolerance (2 minutes walking test), and/or Maximal Volontary Contraction and/or Endurance of quadriceps muscles).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory and oxidative stress parameters after antioxidant supplementation</measure>
    <time_frame>duration study 3 years</time_frame>
    <description>T0 evaluations spirometry, electrocardiogram, holter,Magnetic Resonance imaging of the both thighs,estimation muscle oxygen consumption during acute exercise . T7 venous blood samples (oxidative stress inflammatory markers)needle biopsy of the vastus lateralis muscle (oxidative stress inflammatory markers). analysis oxidative stress on muscle biochemical analyses.T7 patient receives placebo or antioxidant supplementation corresponding randomly-assigned trial. After 17 weeks supplementation the subjects will obtain venous blood samples and needle biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in muscular function after antioxidant supplementation</measure>
    <time_frame>duration study 3 years</time_frame>
    <description>T0 evaluations spirometry, electrocardiogram, holter Magnetic Resonance imaging of the both thighs,estimation muscle oxygen consumption . T7 venous blood samples (oxidative stress inflammatory markers)needle biopsy of the vastus lateralis muscle (oxidative stress inflammatory markers). This one-week lap's time is needed to avoid potential confounding effects of exercise-induced oxidative stress on muscle biochemical analyses.T7 patient receives placebo or antioxidant supplementation corresponding randomly-assigned trial. After 17 weeks supplementation venous blood samples and needle biopsy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Facioscapulohumeral Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>vitamins minerals</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VitE 400/d, vitC 500mg/d, Se 200µg/d (selenomethionine), Zn 25 mg/d gluconate Venous blood samples( analysis oxidative stress inflammatory markers) Needle biopsy of the vastus lateralis muscle (analysis oxidative stress inflammatory markers)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Supplementation 17 weeks placebo venous blood samples (analysis of oxidative stress inflammatory markers) needle biopsy of the vastus lateralis muscle</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Taking of blood</intervention_name>
    <description>Taking venous blood samples to analyse oxidant stress</description>
    <arm_group_label>vitamins minerals</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>needle biopsy of the vastus lateralis muscle</intervention_name>
    <description>T0 needle biopsy of the vastus lateralis muscle (analysis of oxidative stress and inflammatory markers)During 17 weeks supplementation by Vit E, C , Zn Se After 17 weeks: veinous blood samples and needle biopsy</description>
    <arm_group_label>vitamins minerals</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vit C Vit E Zn Se</intervention_name>
    <description>T0 venous blood samples and needle biopsy of the vastus lateralis muscle During 17 weeks vit E 400mg/d, Se 200µg/d, Vit C 500mg/day, Zn 25 mg/d After the supplementation of 17 weeks:venous blood samples and needle biopsy of the vastus lateralis muscle</description>
    <arm_group_label>vitamins minerals</arm_group_label>
    <other_name>FSHD</other_name>
    <other_name>Antioxidant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo Vit E Placebo Vit C Zn Se</intervention_name>
    <description>venous blood samples and needle biopsy</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  FSHD patients will be recruited on the basis of:

               -  The number of repeat units (4 to 9)

               -  FSHD patients with a positive family history for FSHD

               -  Not confined to a wheelchair

               -  No smokers

               -  No associated co-morbidity (cardiac or pulmonary disease, diabetes etc.)

               -  No Medications or nutritional supplementation (vitamins and/or antioxidants) at
                  the time of the study

               -  No HIV positive

        Exclusion Criteria:

          -  No consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jacques JM Mercier, MD, PhD</last_name>
    <phone>33(4)67335908</phone>
    <email>jacques.mercier@univ-montp1.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Montpellier University Hospital- Saint Eloi Hospital</name>
      <address>
        <city>Montpellier</city>
        <state>Languedoc-Roussillon</state>
        <zip>34294</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques JM Mercier, MD, PhD</last_name>
      <phone>33(4)67335908</phone>
      <email>jacques.mercier@univ-montp1.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques mercier, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2012</study_first_submitted>
  <study_first_submitted_qc>May 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2012</study_first_posted>
  <last_update_submitted>May 9, 2012</last_update_submitted>
  <last_update_submitted_qc>May 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FSHD</keyword>
  <keyword>Antioxidants</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Muscle function</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Activity</keyword>
  <keyword>(FSHD;4q35)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Facioscapulohumeral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

